REGENXBIO Inc. (RGNX)
NASDAQ: RGNX · Real-Time Price · USD
8.19
-0.32 (-3.76%)
Aug 1, 2025, 4:00 PM - Market closed
REGENXBIO Employees
REGENXBIO had 353 employees as of December 31, 2024. The number of employees increased by 9 or 2.62% compared to the previous year.
Employees
353
Change (1Y)
9
Growth (1Y)
2.62%
Revenue / Employee
$443,960
Profits / Employee
-$446,711
Market Cap
412.68M
Employees Chart
Employees History
| Date | Employees | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 353 | 9 | 2.62% |
| Dec 31, 2023 | 344 | -57 | -14.21% |
| Dec 31, 2022 | 401 | 29 | 7.80% |
| Dec 31, 2021 | 372 | 66 | 21.57% |
| Dec 31, 2020 | 306 | 49 | 19.07% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| UnitedHealth Group | 400,000 |
| Johnson & Johnson | 138,100 |
| Thermo Fisher Scientific | 125,000 |
| Abbott Laboratories | 114,000 |
| AstraZeneca | 94,300 |
| Novo Nordisk | 77,349 |
| Novartis AG | 75,883 |
| Merck & Co. | 75,000 |
RGNX News
- 2 days ago - REGENXBIO to Host Conference Call on August 7 to Discuss Second Quarter 2025 Financial Results and Operational Highlights - PRNewsWire
- 22 days ago - REGENXBIO Announces Publication of Preclinical Results Demonstrating Functional Benefits of Novel Microdystrophin Construct in RGX-202 Investigational Gene Therapy for Duchenne Muscular Dystrophy - PRNewsWire
- 2 months ago - Regenxbio's RGX-121 Could Become The New Standard Of Care In Hunter Syndrome - Seeking Alpha
- 2 months ago - Early Wins: RegenXBio's Gene Therapy Helps Duchenne Patients Walk Stronger, Longer - Benzinga
- 2 months ago - REGENXBIO REPORTS NEW POSITIVE FUNCTIONAL DATA FROM PHASE I/II AFFINITY DUCHENNE® TRIAL OF RGX-202 - PRNewsWire
- 2 months ago - REGENXBIO to Host Webcast Discussing Interim Functional Data from the Phase I/II AFFINITY DUCHENNE® Trial of RGX-202 - PRNewsWire
- 2 months ago - REGENXBIO Announces Strategic Royalty Monetization Agreement for Up to $250 Million - PRNewsWire
- 2 months ago - FDA Accepts Biologics License Application for Mucopolysaccharidosis II Treatment - PRNewsWire